Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU).
作者： John Nemunaitis , John Cox , Wally Meyer , Alice Courtney , Gabriele Mues
DOI: 10.1097/00000421-199710000-00020
关键词:
摘要: Objective: To determine the prognostic role of a K-ras mutation in tumor tissue patients with refractory colon cancer who received irinotecan hydrochloride (CPT-11). Methods: DNA was extracted from paraffin-stored 35 progressive failing treatment 5-fluorouracil subsequently CPT-11 (100 mg/m2 i.v. per week × 4 weeks 2 off course). The first exon gene amplified by polymerase chain reaction using K-ras-specific primers followed mutant enrichment sequencing. Survival differences were compared those normal status. Results: A total 21 had sequence and 14 [GAT, n = 7; TGT, 3; GCT, AGT, GTT, GAC (codon 13), 1 each]. Median survival ras time 332 days 169 for (p 0.0036). No age, sex, stage, surgical treatment, or chemotherapy observed. Conclusion: Determination presence may predict after receive CPT-11.
elsevier.com
sci-hub.st 参考文章(19)
M Fukuoka, H Niitani, A Suzuki, M Motomiya, K Hasegawa, Y Nishiwaki, T Kuriyama, Y Ariyoshi, S Negoro, N Masuda, A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. Journal of Clinical Oncology. ,vol. 10, pp. 16- 20 ,(1992) , 10.1200/JCO.1992.10.1.16
Jean Benhattar, Lorena Losi, Pascal Chaubert, Jean-Claude Givel, Jose Costa, Prognostic significance of K-ras mutations in colorectal carcinoma Gastroenterology. ,vol. 104, pp. 1044- 1048 ,(1993) , 10.1016/0016-5085(93)90272-E
K T Riabowol, R J Vosatka, E B Ziff, N J Lamb, J R Feramisco, Microinjection of fos-specific antibodies blocks DNA synthesis in fibroblast cells. Molecular and Cellular Biology. ,vol. 8, pp. 1670- 1676 ,(1988) , 10.1128/MCB.8.4.1670
A Hall, A biochemical function for Ras--at last Science. ,vol. 264, pp. 1413- 1414 ,(1994) , 10.1126/SCIENCE.8197454
K. J. Scanlon, L. Jiao, T. Funato, W. Wang, T. Tone, J. J. Rossi, M. Kashani-Sabet, Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein Proceedings of the National Academy of Sciences of the United States of America. ,vol. 88, pp. 10591- 10595 ,(1991) , 10.1073/PNAS.88.23.10591
K. J. Scanlon, H. Ishida, M. Kashani-Sabet, Ribozyme-mediated reversal of the multidrug-resistant phenotype Proceedings of the National Academy of Sciences of the United States of America. ,vol. 91, pp. 11123- 11127 ,(1994) , 10.1073/PNAS.91.23.11123
B. Giovanella, J. Stehlin, M. Wall, M. Wani, A. Nicholas, L. Liu, R Silber, M Potmesil, DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts Science. ,vol. 246, pp. 1046- 1048 ,(1989) , 10.1126/SCIENCE.2555920
L. Kerr, J. Holt, L. Matrisian, Growth factors regulate transin gene expression by c-fos-dependent and c-fos-independent pathways. Science. ,vol. 242, pp. 1424- 1427 ,(1988) , 10.1126/SCIENCE.2462278
K.J. Scanlon, M. Kashani-Sabet, T. Tone, T. Funato, Cisplatin resistance in human cancers. Pharmacology & Therapeutics. ,vol. 52, pp. 385- 406 ,(1991) , 10.1016/0163-7258(91)90033-I
K. J. Scanlon, M. Kashani-Sabet, Elevated expression of thymidylate synthase cycle genes in cisplatin-resistant human ovarian carcinoma A2780 cells. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 85, pp. 650- 653 ,(1988) , 10.1073/PNAS.85.3.650